Berta Renedo Miró
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Berta Renedo Miró has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alice Andalò
Data Unit IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” Meldola Italy
1 shared publication - Andrea Prochowski Iamurri
Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
1 shared publication - Aurora Fernández-Polo
Servicio de Farmacia, Hospital Universitario Vall d'Hebron, Barcelona, Spain
1 shared publication - Enrique Trilla
Department of Surgery Universitat Autònoma de Barcelona Bellaterra Spain
1 shared publication - Fabio Ferroni
Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli n. 40, 47014 Meldola, Italy
1 shared publication - Filippo Merloni
Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
1 shared publication
Latest Publications
- 12 August 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Optimizing Posaconazole Suspension Prophylaxis in Pediatric Patients: The Key Role of Therapeutic Drug Monitoring
Background: Posaconazole suspension is widely used for the prophylaxis of breakthrough invasive fungal infections in high-risk children. Due to its low bioavailability and high pharmacokinetic variability, therapeutic drug monitoring (TDM) is recommended. Objectives: To describe prophylactic posaconazole suspension TDM in children, evaluate its effectiveness and investigate factors influencing its pharmacokinetics. Methods: Retrospective observational study from 2017–2023, including consecutive patients trough ]). Results: Seventy-one patients were included (median age 4.8 [interquartile range, IQR 2.4–8.9] years). The most frequent underlying condition was inborn errors of immunity (23, 32.4%); 55 patients (77.5%) had undergone hematopoietic stem-cell transplantation. Out of 373 C trough , 178 (47.7%) were within the therapeutic range and 187 (50.1%) were subtherapeutic. The median posaconazole dose was significantly higher in patients under 2 (17.4 [IQR 12.6–23.7] mg/kg/day vs. 13.4 [IQR 12.0–18.4] mg/kg/day, P < 0.001). Nausea/vomiting (odds ratio [OR] 4.89; 95% confidence interval 2.09–11.44; P = 0.0003) and concomitant proton pump inhibitor use (OR 3.03; 95% confidence interval 1.15–7.95; P = 0.0248) were significantly associated with subtherapeutic C trough . Proven breakthrough invasive fungal infections occurred in 3 (4.2%) patients, with no statistically significant difference in subtherapeutic C trough values compared with the rest of the cohort ( P = 0.128). Toxicity was not related to supratherapeutic C trough . Conclusions: Our study highlights the importance of TDM in pediatric patients receiving posaconazole suspension, particularly those with risk factors associated with subtherapeutic C trough . Although further studies are needed to define the optimal dosage in children under 2, our findings suggest that these patients should receive at least 15 mg/kg/day.
- 12 August 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Optimizing Posaconazole Suspension Prophylaxis in Pediatric Patients: The Key Role of Therapeutic Drug Monitoring
Background: Posaconazole suspension is widely used for the prophylaxis of breakthrough invasive fungal infections in high-risk children. Due to its low bioavailability and high pharmacokinetic variability, therapeutic drug monitoring (TDM) is recommended. Objectives: To describe prophylactic posaconazole suspension TDM in children, evaluate its effectiveness and investigate factors influencing its pharmacokinetics. Methods: Retrospective observational study from 2017–2023, including consecutive patients trough ]). Results: Seventy-one patients were included (median age 4.8 [interquartile range, IQR 2.4–8.9] years). The most frequent underlying condition was inborn errors of immunity (23, 32.4%); 55 patients (77.5%) had undergone hematopoietic stem-cell transplantation. Out of 373 C trough , 178 (47.7%) were within the therapeutic range and 187 (50.1%) were subtherapeutic. The median posaconazole dose was significantly higher in patients under 2 (17.4 [IQR 12.6–23.7] mg/kg/day vs. 13.4 [IQR 12.0–18.4] mg/kg/day, P < 0.001). Nausea/vomiting (odds ratio [OR] 4.89; 95% confidence interval 2.09–11.44; P = 0.0003) and concomitant proton pump inhibitor use (OR 3.03; 95% confidence interval 1.15–7.95; P = 0.0248) were significantly associated with subtherapeutic C trough . Proven breakthrough invasive fungal infections occurred in 3 (4.2%) patients, with no statistically significant difference in subtherapeutic C trough values compared with the rest of the cohort ( P = 0.128). Toxicity was not related to supratherapeutic C trough . Conclusions: Our study highlights the importance of TDM in pediatric patients receiving posaconazole suspension, particularly those with risk factors associated with subtherapeutic C trough . Although further studies are needed to define the optimal dosage in children under 2, our findings suggest that these patients should receive at least 15 mg/kg/day.
- Open Access
- 10 April 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (4)
European validation of the Barcelona magnetic resonance predictive model for significant prostate cancer detection in prostate biopsies
- 10 April 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (4)
Open AccessEuropean validation of the Barcelona magnetic resonance predictive model for significant prostate cancer detection in prostate biopsies